好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Determination of Prevalence of Posterior Reversible Encephalopathy Syndrome (PRES) and Its Association with Cerebral Infarction, and Outcome in the Nationwide Inpatient Sample, 2016-2018
Cerebrovascular Disease and Interventional Neurology
P16 - Poster Session 16 (8:00 AM-9:00 AM)
13-002

To assess the potential prevalence of Posterior Reversible Encephalopathy syndrome (PRES) and its association with cerebral infarction (CI)  in a nationwide database. We also investigated the outcome of CI in association to PRES in terms of inpatient mortality rate and length of stay in the hospital. 

PRES is a very rare syndrome, and its impact on stroke is not well understood. It can be irreversible and life threatening when it is presented with stroke. In this regard, more research studies are needed to improve the outcomes.  

 

We assessed data in terms of prevalence of PRES and its association with CI from the Nationwide Inpatient Sample (NIS) from 2016 to 2018 using ICD code 10. We also determined the outcome in terms to inpatient mortality rate and average length of stay (LOS), a P value of <0.05 was considered significant.  

 

Ia total of 21  million patients, the frequency of PRES was 0.03% for all patients compared to 2.2% (OR 4.6, CI 4.23-5.01 p<0.001) in cerebral infarct patients. The prevalence of PRES was significantly higher in  females (female, 63.5vs male, 36.5%, p< 0.001) and Caucasians (Caucasians 63%, vs others, 37%  p<0.001) In patients with CI in association to PRES, the outcome was worse in terms of mortality  (11% vs 6%p<0.001) as well as  LOS (12 vs  days, p=0.001)In  addition, we have observed that HTN, pre-eclampsia, polyarteritis nodosa, cryoglobulinemia, porphyria  were associated with PRES ( p<0.001) in this data base. 

 PRES was observed to be associated with enhanced risk of CI. This association was associated with worse outcomeMeasures designed to prevent the development of  PRES, or to limit its severity, are warranted.  

Authors/Disclosures
Prabandh R. Buchhanolla, MBBS
PRESENTER
Dr. Buchhanolla has nothing to disclose.
Shyamal C. Bir, MD (Tallahassee Memorial Hospital) Dr. Bir has nothing to disclose.
Alexis Angelette, MD (New York Presbyterian) Dr. Angelette has nothing to disclose.
Annie Lewis Ms. Lewis has nothing to disclose.
No disclosure on file
No disclosure on file
Vijayakumar Javalkar, MD, MCh, FAAN (LSUHSC Shreveport) Dr. Javalkar has nothing to disclose.
Oleg Y. Chernyshev, MD, PhD, FAAN (LSUHSC-Shreveport) Dr. Chernyshev has nothing to disclose.
Roger E. Kelley, Jr., MD, FAAN (LSU Health Sciences Center) Dr. Kelley has nothing to disclose.